Axonics Modular Technologies
Novel sacral neuromodulation system for treating overactive bladder
Axonics has developed a novel and potentially best-in-class implantable sacral neuromodulation (SNM) system for the treatment of overactive bladder and faecal incontinence.
It will be the smallest fully implantable, and first rechargeable SNM device, and is expected to work in the body for up to 15 years.
CEO Raymond Cohen
Advent Contact Shahzad Malik
Advent invested in the Series B in 2015.
Exited Investment
Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million
Press Release. Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation…
Read More
Bayer’s Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
Press Release. October 24, 2025 Bayer’s Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause This approval is supported by data…
Read More
Boston Scientific Announces Agreement to Acquire Nalu Medical, Inc.
Press Release. Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into…
Read More
Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG
Press Release. Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG September 3, 2025 SAN CARLOS, Calif., September 3, 2025…
Read More
